Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.DCAF5 expression is reduced in renal clear cell carcinoma and correlates with poor prognosis. This protein shows potential as an immunotherapy biomarker, outperforming traditional markers like TMB.
Area Of Science
- Oncology
- Molecular Biology
- Immunotherapy
Background
- DCAF5 is a ubiquitin ligase component with potential to reverse malignant phenotypes.
- Limited research on DCAF5 hinders its development as a cancer treatment target.
Purpose Of The Study
- To investigate DCAF5 expression in renal clear cell carcinoma (RCC).
- To explore the correlation between DCAF5 expression and patient outcomes and immunotherapy response.
Main Methods
- Immunohistochemical analysis of DCAF5 in RCC tissues versus adjacent non-neoplastic tissues.
- Survival analyses using public databases (UCSC Xena, TCGA, GTEx).
- Correlation analysis of DCAF5 expression with immune scores and cell infiltration.
Main Results
- DCAF5 expression is significantly reduced in RCC tissues compared to normal tissues.
- Lower DCAF5 expression correlates with higher tumor grade and poorer patient outcomes.
- DCAF5 expression correlates with immune cell infiltration and scores across various cancers, showing potential as an immunotherapy biomarker.
- Gene amplification is the primary genetic alteration for DCAF5.
Conclusions
- DCAF5 has context-dependent dual roles in cancer and is a promising prognostic and immunotherapy biomarker.
- DCAF5 demonstrates superior predictive value over TMB for immunotherapy response.
- DCAF5 is particularly relevant for immunotherapy personalization in SMARCB1-deficient malignancies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
